Dr. Philip M. Arlen to give scientific presentation at two conferences
Dr. Philip M Arlen, MD, President and CEO is Presenting the Following Talk at the...
06Oct
25Aug
Synthetic Antibody Rallies Immune Cells Against Ovarian Cancer
NIH Intramural Research Program (IRP) highlights Precision Biologics NEO-201 monoclonal antibody.
15Jul
Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer
Precision Biologics in conjunction with our research collaborators at the National Cancer Institute (NCI) have...
22Jun
Precision Biologics and the National Cancer Institute deliver 2 Poster Presentations at the AACR virtual meeting June 22-24th, 2020
Precision Biologics along with our collaborators at the National Cancer Institute present research data using...
30Apr
Results of Precision Biologics Phase 2 Colorectal Cancer Study Published in Clinical Cancer Research
Precision Biologics announces that the results of the Phase II Clinical Trial using its lead...
01Mar
Precision Biologics to Deliver two Oral Presentations on our Clinical and Scientific Programs at the World Immunotherapy Conference, March 2-4, 2020, San Diego, CA
Dr Massimo Fantini, Senior Scientist is Presenting the following Talk entitled: "Mechanisms of action of...
06Nov
SITC 2019
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T...
15Oct
Novel Targets Of Neoantigens In Monoclonal Antibodies
Philip M. Arlen, M.D. Summary: Target is broadly expressed in multiple solid tumors. Exhibits both ADCC and CDC...
01Nov
The National Cancer Institute Opens Clinical Trial Testing Safety and Dosing of NEO-201 Antibody in Patients with Advanced Cancer
Clinical trial tests safety and dosing of NEO-201 antibody in patients with advanced cancer NIH 11/01/2018 Patients...
08Jan
Precision Biologics manuscript on our NEO-201 Antibody article published in Frontiers in Immunology
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas